血小板反映EVAR术后II型内漏的转归
该回顾性研究纳入2007至2015年249例腹主动脉瘤EVAR患者,比较术前与术后第1至7天血小板计数。恶性T2E组术后第7天血小板显著低于完成组和良性T2E组;血小板比值低于113%是T2E患者瘤囊扩大的独立预测因素。
要点
- EVAR术后第7天血小板计数较低与恶性II型内漏相关。
- 血小板比值低于113%的T2E患者瘤囊扩大风险更高。
- 术后第7天血小板比值可作为T2E风险分层参考指标。
核心结论
- 恶性T2E患者术后第7天血小板计数显著低于完成EVAR或良性T2E患者。
- 术后第7天较低血小板计数可能是T2E患者瘤囊扩大的危险因素。
研究设计与样本
- 回顾性研究,2007至2015年249例因腹主动脉瘤接受EVAR治疗的患者。
- 平均随访3.5±0.2年,比较术前与术后第1至7天血小板计数。
- 恶性T2E定义为瘤囊扩大或转为I型/III型内漏,其余T2E为良性。
主要发现
- T2E见于70例(28%),完成组179例,恶性T2E 33例,良性T2E 37例。
- 术后第7天恶性T2E组血小板计数显著低于完成组和良性T2E组(168×10^3/μL vs 207×10^3/μL和201×10^3/μL;P=.0124)。
- T2E-LP组无再干预生存率低于完成组(3年时66.4%±8.0% vs 71.9%±4.0%;P=.0031)。
- T2E-LP组累积瘤囊扩大率显著高于T2E-HP组(3年时34.6%±8.2% vs 20.6%±8.2%;P=.0105)。
- 多因素分析显示T2E-LP是T2E患者瘤囊扩大的唯一显著预测因素(HR=2.60;P=.0355)。
关键数值与推荐
- 术后第7天血小板与基线比值截断值为113%(敏感度79%,特异度58%)。
- T2E-HP定义为血小板比值≥113%,T2E-LP定义为<113%。
- T2E-HP组27例,T2E-LP组43例。
临床怎么用
- EVAR术后可监测第7天血小板比值,辅助识别恶性T2E高危患者。
- 血小板比值低于113%的T2E患者应加强瘤囊扩大监测和随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The management of type II endoleak (T2E) remains controversial because of the heterogeneous outcome. For blood-based screening to detect malignant T2E, we focused on platelets after endovascular aneurysm repair (EVAR) and compared them with the prognosis of T2Es. METHODS: From 2007 to 2015, there were 249 patients treated with EVAR for abdominal aortic aneurysm who were evaluated retrospectively. The mean follow-up period was 3.5 ± 0.2 years. T2Es that had aneurysm sac enlargement or converted to type I or type III endoleak were defined as malignant; the other T2Es were considered benign. Cases without any complications, including T2E, were defined as completed. We compared the platelet count on postoperative days (PODs) 1 to 7 with preoperative baseline values among the three groups. Sequentially, we calculated the cutoff of the platelet ratio on POD 7 to the baseline value in relation to malignant T2E using receiver operating characteristic analysis, and the cutoff ratio was 113% (sensitivity, 79%; specificity, 58%). We then reclassified T2E patients into T2E-high platelet (T2E-HP; ≥113%) or T2E-low platelet (T2E-LP; <113%) groups. The influence of platelets on T2E was evaluated with reintervention rate and cumulative aneurysm sac enlargement rate using the Kaplan-Meier method. RESULTS: T2Es were found in 70 patients (28%), and 179 patients were assigned to the completed group. Malignant and benign T2Es were found in 33 and 37 patients, respectively. No difference was found in the preoperative baseline values. On POD 7, the platelet count in the malignant T2E group was significantly lower than that in the completed and benign T2E groups (168 × 103/μL vs 207 × 103/μL and 201 × 103/μL; P = .0124). Then, 27 and 43 patients were assigned to the T2E-HP and T2E-LP groups, respectively. The reintervention-free survival rate in the T2E-LP group was lower than that in the completed group (at 3 years, 66.4% ± 8.0% vs 71.9% ± 4.0%; P = .0031). Among T2E patients, the cumulative aneurysm sac enlargement rates in the T2E-LP group were significantly higher than those in the T2E-HP group (at 3 years, 34.6% ± 8.2% vs 20.6% ± 8.2%; P = .0105). Univariate Cox proportional hazards analysis for the cumulative aneurysm sac enlargement rates among T2E patients showed that sex, dual antiplatelet therapy, and lower platelet ratio (<113%) were significant predictors; multivariate analysis showed that T2E-LP was the only significant predictor (hazard ratio, 2.60; P = .0355). CONCLUSIONS: The platelet count of patients with malignant T2Es on POD 7 was definitively lower than that of patients with completed EVAR or with benign T2Es. The lower platelet count on POD 7 could be a risk factor for aneurysm sac enlargement among patients with T2Es.
引用
- Inoue K, Furuyama T, Kurose S, et al. Platelets reflect the fate of type II endoleak after endovascular aneurysm repair. J Vasc Surg. 2020. PMID: 31980245. doi:10.1016/j.jvs.2019.09.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。